Vascular disease

Dr. Lawrence Garcia Joins The Vascular Care Group, Newton-Wellesley

Retrieved on: 
星期二, 九月 20, 2022
Health, Practice Management, Other Health, Managed Care, General Health, Cardiology, Definitive, MPH, Degenerative disease, Faculty, Time, American College, Master of Science, Tufts University School of Medicine, Beth Israel Deaconess Medical Center, Society, Health, Boston (magazine), Coronary artery disease, Medicare Physician Group Practice (PGP) Demonstration, Patient, Clinical trial, Physician, MBA, SCAI, University of Iowa Hospitals and Clinics, Moyamoya disease, Associate, Diagnosis, Board, FAHA, Harvard Medical School, Research, Vascular disease, American College of Cardiology, Interventional cardiology, Hospital, American Heart Association, Multimedia, FACC, University, RPVI, ST, FACS, Dentistry, Pharmaceutical industry, Medicine, Medical imaging, Cardiology, MD, Parkland Memorial Hospital, Medicine

The Vascular Care Group, a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, is pleased to announce that Dr. Lawrence Garcia has joined the Wellesley center.

Key Points: 
  • The Vascular Care Group, a state-of-the art practice committed to the prevention, diagnosis and treatment of vascular disease, is pleased to announce that Dr. Lawrence Garcia has joined the Wellesley center.
  • Lawrence A. Garcia, MD, FACC, FAHA, FSCAI, is a Board-certified interventional cardiologist with a focus on peripheral vascular disease.
  • Prior to joining The Vascular Care Group, Dr. Garcia received his undergraduate and doctoral degrees from the University of Arizona.
  • The Vascular Care Group (TVCG) is a growing group practice committed to the prevention, diagnosis and treatment of vascular disease.

Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) Celebrates 1M Procedures

Retrieved on: 
星期四, 九月 15, 2022
Technology, Surgery, Hospitals, Health Technology, Cardiology, Software, Hardware, Managed Care, Health, Data Management, Society for Vascular Surgery, Safety, Database, Registry, Publication, Knowledge, Quality, Fivos Constantinou, Health, Radiology, Patient, Initiative, SVS, Data collection, Hotel manager, Surgeon, Cardiology, Vascular disease, Society, Medical imaging, MD

The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) clinical registry announced today it has now collected over one million procedures in its database.

Key Points: 
  • The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) clinical registry announced today it has now collected over one million procedures in its database.
  • The organization is staffed by experts in vascular disease, quality improvement, and clinical analysis, with 250 volunteer physicians lending additional support.
  • The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) is governed by the SVS Patient Safety Organization (SVS PSO), a wholly owned subsidiary of the Society for Vascular Surgery, which provides oversight of data sharing arrangements, key outcome and quality measure analyses, and dissemination of information to participating providers.
  • SVS VQI comprises vascular surgeons, cardiologists, radiologists and specialists who perform vascular procedures collected in the VQI Registries, as well as Quality Improvement professionals, data managers and others dedicated to improving patient outcomes.

The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) Enter a Strategic Partnership for the Study of NASH

Retrieved on: 
星期三, 九月 7, 2022
Beaujon Hospital, Partnership, Vascular disease, Paris Diderot University, CEO, National Institute, Imaging, SIB, Artificial intelligence, Liver, INSERM, Trial of the century, CEA, Seminal vesicles, Pathology, Artificiality, Digital pathology, Commissariat, Physics, Swiss Institute of Bioinformatics, Fatty liver disease, Diagnosis, Diabetes, Medical research, Inflammation, Type 2 diabetes, Fibrosis, GLOBE, Biostatistics, Leadership, Princeton University, NASH, University, Assistance, Data, Patient, QUID, Medical imaging, T2D, Beaujon

The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.

Key Points: 
  • The clinical study involves 600 type 2 diabetic patients who are receiving a liver biopsy as part of standard care.
  • This dataset will enrich the data collected and enable the consortium to discover novel histological phenotypes of NASH in T2D patients.
  • Its multivendor platform, FibroNest, is delivered worldwide via the cloud and used in multiple pre-clinical and clinical studies across several fibrotic conditions.
  • For more information about FibroNest and PharmaNest, visit www.pharmanest.com and www.fibronest.com

First-on-Podium Data from 21 Vascular Interventional Clinical Trials to Be Presented at The VEINS and VIVA 2022

Retrieved on: 
星期四, 九月 1, 2022
Treatment, Wynn Las Vegas, Research, Virtual, Awareness, Health and Quality of Life Outcomes, Subgroup analysis, Vascular disease, Physician, Diagnosis, Education, Multimedia, Human, STRIDE, Disrupt, Multicenter trial, Observational study, Blood vessel, VIVA, Lithotripsy, Pharmaceutical industry, Medicine, Medical imaging

VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.

Key Points: 
  • VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.
  • The VEINS (Venous Endovascular INterventional Strategies) is a comprehensive education symposium focused on the diagnosis, intervention, and management of venous disorders.
  • VIVA and The VEINS bring together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world.
  • Attendees for both events include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

Retrieved on: 
星期三, 八月 10, 2022
FDA, Principal, CEO, Technology, CE marking, Growth, PAD, Coronary artery disease, Patient, CAT, POBA, Peripheral artery disease, Peripheral vascular examination, IDE, Stent, Vascular disease, DEB, Medicine, Pharmaceutical industry

Enrollment will begin in the SELUTION SLR IDE SFA study later this year.

Key Points: 
  • Enrollment will begin in the SELUTION SLR IDE SFA study later this year.
  • "This is a significant milestone for MedAlliance: we are the first non-paclitaxel drug coated balloon to receive IDE approval, and now the first to have two applications approved.
  • SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
  • SELUTION SLR is available in Europe and all other countries where the CE Mark is recognized.

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

Retrieved on: 
星期三, 八月 10, 2022
FDA, Principal, CEO, Technology, CE marking, Growth, PAD, Coronary artery disease, Patient, CAT, POBA, Peripheral artery disease, Peripheral vascular examination, IDE, Stent, Vascular disease, DEB, Medicine, Pharmaceutical industry

Enrollment will begin in the SELUTION SLR IDE SFA study later this year.

Key Points: 
  • Enrollment will begin in the SELUTION SLR IDE SFA study later this year.
  • "This is a significant milestone for MedAlliance: we are the first non-paclitaxel drug coated balloon to receive IDE approval, and now the first to have two applications approved.
  • SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
  • SELUTION SLR is available in Europe and all other countries where the CE Mark is recognized.

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

Retrieved on: 
星期三, 八月 10, 2022
FDA, Principal, CEO, Technology, CE marking, Growth, PAD, Coronary artery disease, Patient, CAT, POBA, Peripheral artery disease, Peripheral vascular examination, IDE, Stent, Vascular disease, DEB, Medicine, Pharmaceutical industry

Enrollment will begin in the SELUTION SLR IDE SFA study later this year.

Key Points: 
  • Enrollment will begin in the SELUTION SLR IDE SFA study later this year.
  • "This is a significant milestone for MedAlliance: we are the first non-paclitaxel drug coated balloon to receive IDE approval, and now the first to have two applications approved.
  • SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
  • SELUTION SLR is available in Europe and all other countries where the CE Mark is recognized.

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

Retrieved on: 
星期三, 八月 10, 2022
FDA, Principal, CEO, Technology, CE marking, Growth, PAD, Coronary artery disease, Patient, CAT, POBA, Peripheral artery disease, Peripheral vascular examination, IDE, Stent, Vascular disease, DEB, Medicine, Pharmaceutical industry

Enrollment will begin in the SELUTION SLR IDE SFA study later this year.

Key Points: 
  • Enrollment will begin in the SELUTION SLR IDE SFA study later this year.
  • "This is a significant milestone for MedAlliance: we are the first non-paclitaxel drug coated balloon to receive IDE approval, and now the first to have two applications approved.
  • SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
  • SELUTION SLR is available in Europe and all other countries where the CE Mark is recognized.

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

Retrieved on: 
星期二, 八月 9, 2022
FDA, Principal, CEO, Technology, CE marking, Growth, PAD, Coronary artery disease, Patient, CAT, POBA, Peripheral artery disease, Peripheral vascular examination, IDE, Stent, Vascular disease, DEB, Medicine, Pharmaceutical industry

Enrollment will begin in the SELUTION SLR IDE SFA study later this year.

Key Points: 
  • Enrollment will begin in the SELUTION SLR IDE SFA study later this year.
  • "This is a significant milestone for MedAlliance: we are the first non-paclitaxel drug coated balloon to receive IDE approval, and now the first to have two applications approved.
  • SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral artery disease in February 2020 and for the treatment of coronary artery disease in May 2020.
  • SELUTION SLR is available in Europe and all other countries where the CE Mark is recognized.

Endologix Receives CE Mark Certification under EU-MDR for AFX®2 Endovascular AAA System

Retrieved on: 
星期四, 八月 4, 2022
Health, Medical Devices, Cardiology, MDD, Freedom, Union, Vascular disease, Patient, PAD, AFX, AAA, Quality, Safety, European Commission, Moyamoya disease, Medical Devices Directive, Randomized controlled trial, Technology, Aortic aneurysm, Aneurysm, Forward-looking statement, CEO, Certification, EVAR, Royal commission, Medical device, Acquisition, MDR, EU

Endologix LLC , a privately held global medical device company dedicated to improving patients lives with innovative interventional treatments for vascular disease, announced that is has received CE Mark Certification under the new EU Medical Devices Regulation [EU-MDR [(Regulation (EU) 2017/745)] for its AFX2 Endovascular AAA System.

Key Points: 
  • Endologix LLC , a privately held global medical device company dedicated to improving patients lives with innovative interventional treatments for vascular disease, announced that is has received CE Mark Certification under the new EU Medical Devices Regulation [EU-MDR [(Regulation (EU) 2017/745)] for its AFX2 Endovascular AAA System.
  • CE Mark certification under the new requirements is a high-bar and we are proud of this significant company achievement.
  • Meeting the rigor of the new framework is an important milestone for our AFX2 System, said Elisa Hebb, Endologixs EVP of Medical, Clinical, Regulatory Affairs and Quality.
  • Endologixs current commercial EVAR products include the AFX2 Endovascular AAA System and the ALTO Abdominal Stent Graft System.